Research and Markets: Warehousing in HCV - 2013 Report Contains Up-To-The-Minute Information on Patient Treatment Programmes in HCV
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/smm662/warehousing_in_hcv) has announced the addition of the "Warehousing in HCV" report to their offering.
Warehousing of HCV patients reaches new high: physicians wait expectantly for new interferon-free treatments
A new study conducted by independent healthcare market research specialist Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now warehousing patients (holding off treatment) in expectation of more efficacious and tolerable new therapies. In a special report conducted alongside the company's regular Therapy Watch tracking study into HCV, hepatologists and infectious disease specialists were asked specific questions around the issue of warehousing and new treatments. The survey reveals that, with over 9 in 10 doctors now warehousing some of their patients, over half (51%) of HCV patients eligible for treatment in the US are not currently undergoing treatment.
For the past two decades, the therapies available for HCV have been very limited, offering low success rates and harsh side effects. New drugs from Vertex (Incivek) and Merck (Victrelis) have been welcomed because they are more effective, but they still need to be given with Interferon. Interferon is the component that causes the strongest side effects, so a lot of patients still find the existing available treatment programmes, which can take up to a year to complete, intolerable. The race is on for a number of pharmaceutical companies to release new interferon-free regimens, which are currently in the late stages of development and due to be released within the next 6-12 months.
The survey found that 62% of patients currently being warehoused will only start treatment once an interferon-free regimen becomes available. Almost 80% of doctors stated that an interferon-free therapy is the most important feature likely to increase uptake amongst untreated patients.
Gilead's interferon-free product sofosbuvir and Johnson & Johnson's simeprevir appear to lead the field - receiving the highest levels of spontaneous and prompted awareness. However, Abbvie's products ABT 267, ABT 333 and ABT 450 remain contenders for market share, scoring higher than J&J's simeprevir in terms of likelihood to prescribe amongst doctors who are aware of the drugs.
Associate Director Darren Kottler, who manages the survey, commented The findings clearly illustrate that physicians are keen to start their patients on interferon-free alternatives.
For some time Gilead and J&J appeared to lead the race, but it looks like Abbvie's announcement that the US Food and Drug Administration (FDA) were going to fast-track its all-oral triple direct-acting antiviral DAA combination therapy, has had an impact on physician perception.
We will have to wait and see how this all plays out in the market once these new products are released. The new interferon-free regimens and ultimately new generation of protease-inhibitors are certainly going to be positive for many patients currently awaiting treatment for HCV.
For more information visit http://www.researchandmarkets.com/research/smm662/warehousing_in_hcv
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.